Nostrum Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA076756
Nostrum Pharmaceuticals has received an Abbreviated Approval (AP) for ANDA076756, a generic version of Metformin Hydrochloride.
Asset / Drug
Drug and asset intelligence for Nostrum with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.